Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131

Feb 25, 2019

Cellectar Biosciences to Present at the Annual BIO CEO & Investor Conference

Feb 5, 2019

Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference

Jan 23, 2019

Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma

Jan 7, 2019

Cellectar Biosciences to Present at the Biotech Showcase

Jan 3, 2019

Cellectar Granted Japanese Patent for CLR 131

Dec 11, 2018

Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma

Dec 4, 2018

Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update

Nov 13, 2018

Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies

Nov 12, 2018

Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma

Oct 2, 2018